OCT inks development deal with ex-Google AI experts, Hypatia AI

Oxford Cannabinoid Technologies (OCT) today announced the successful completion of 'proof of concept' of its AI-enabled drug discovery asset, which it is developing in collaboration with New York-based tech consultancy, Hypatia AI.

The UK company explained that Hypatia is developing a cutting-edge AI tool that will significantly accelerate OCT’s drug discovery process. By focusing on deep, rigorous insights from vast scientific literature, the asset acts as an endlessly resourceful research assistant ensuring OCT’s scientific team spends less time searching and more time discovering. This targeted, in-depth approach helps researchers to uncover connections and insights that might otherwise be missed.

The asset amplifies OCT’s expertise, enabling its research team to link ideas and explore breakthrough possibilities to harness the therapeutic power of cannabinoids to develop non-addictive pain medications to reduce reliance on opioids, at unprecedented speed, the company claims.